Affiliation:
1. Jiangsu Key Laboratory for Molecular and Medical Biotechnology and College of Life Sciences Nanjing Normal University Nanjing China
2. Department of endocrinology Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University Guangzhou China
Abstract
AbstractThe discovery of alternative medicines with fewer adverse effects is urgently needed for rheumatoid arthritis (RA). Sophoridine (SR), the naturally occurring quinolizidine alkaloid isolated from the leguminous sophora species, has been demonstrated to possess a wide range of pharmacological activities. However, the effect of SR on RA remains unknown. In this study, the collagen‐induced arthritis (CIA) rat model and tumor necrosis factor alpha (TNFα)‐induced fibroblast‐like synoviocytes (FLSs) were utilized to investigate the inhibitory effect of SR on RA. The anti‐arthritic effect of SR was evaluated using the CIA rat model in vivo and TNFα‐stimulated FLSs in vitro. Mechanistically, potential therapeutic targets and pathways of SR in RA were analyzed through drug target databases and disease databases, and validation was carried out through immunofluorescence, immunohistochemistry, and Western blot. The in vivo results revealed that SR treatment effectively ameliorated synovial inflammation and bone erosion in rats with CIA. The in vitro studies showed that SR could significantly suppress the proliferation and migration in TNFα‐induced arthritic FLSs. Mechanistically, SR treatment efficiently inhibited the activation of MAPKs (JNK and p38) and NF‐κB pathways in TNFα‐induced arthritic FLSs. These findings were further substantiated by Immunohistochemistry results in the CIA rat. SR exerts an anti‐arthritic effect in CIA rats through inhibition of the pathogenic characteristic of arthritic FLSs via suppressing NF‐κB and MAPKs (JNK and p38) signaling pathways. SR may have a great potential for development as a novel therapeutic agent for RA treatment.
Funder
National Natural Science Foundation of China